透皮尼古丁治疗和早期帕金森病的进展
Wolfgang H Oertel1,2,3, Hans-Helge Müller4,5, Marcus M Unger6
1Department of Neurology, Philipps University Marburg, Marburg, Germany.
NEJM evidence
|February 6, 2024
概括
在为期一年的试验中,通过皮肤注射的尼古丁并没有减缓帕金森病的进展. 这项研究调查了尼古丁在早期帕金森病患者中的潜在神经保护作用.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 流行病学 流行病学
背景情况:
- 流行病学研究表明,吸烟者患帕金森病的发病率较低.
- 尼古丁被假设在早期帕金森病中可能会减缓疾病的进展.
研究的目的:
- 评估通过皮肤注射尼古丁在减缓早期帕金森病进展方面的疗效.
- 评估尼古丁对52周内统一帕金森病评分表 (UPDRS) 评分的影响.
主要方法:
- 一个双盲,安慰剂控制的多中心试验,涉及163名患有早期帕金森病的患者.
- 参与者接受了通过皮肤注射的尼古丁或安慰剂52周,随后是8周的洗期.
- 主要终点是从基线到60周的总UPDRS得分的变化.
主要成果:
- 60周后,尼古丁组的平均总UPDRS恶化为6.0,而安慰剂组的3.5 (P=0.06).
- 在52周的分析显示,尼古丁组的平均总UPDRS恶化为9.1,而安慰剂组的5.4.
- 常见的不良事件包括尼古丁贴片部位的皮肤影响;34.6%的参与者开始了多巴胺疗法.
结论:
- 通过皮肤注射尼古丁治疗一年没有显著影响减缓早期帕金森病的进展.
- 这些发现不支持尼古丁在帕金森病中赋予神经保护或疾病修饰的假设.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K


